Literature DB >> 7589440

Human pancreatic phospholipase A2 stimulates the growth of human pancreatic cancer cell line.

K Hanada1, E Kinoshita, M Itoh, M Hirata, G Kajiyama, M Sugiyama.   

Abstract

Phospholipase A2 (PLA2) from human pancreas, designated hPLA2-I, functions as a digestive enzyme. Interestingly, the present study demonstrated that the mature form of hPLA2-I stimulated the growth of a human pancreatic cancer cell line MIAPaCa-2, whereas the pro-form was ineffective. PLA2s from Laticauda semifasciata fraction I, Crotalus adamanteus venom, Streptomyces violaceoruber and bee venom, showed no proliferative effect to the growth of MIAPaCa-2. The Scatchard plot analysis revealed that the MIAPaCa-2 cell had a specific binding site for the mature hPLA2-I. The equilibrium binding constant (Kd) and the maximum binding capacity (Bmax) were 2.6 nM and 0.4 fmol/10(6) cells, respectively. These results suggest that the mature hPLA2-I, but not the pro-form, may function as a growth factor of pancreas carcinoma via the specific binding site.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589440     DOI: 10.1016/0014-5793(95)01005-y

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  5 in total

1.  Group II and IV phospholipase A(2) are produced in human pancreatic cancer cells and influence prognosis.

Authors:  M Kashiwagi; H Friess; W Uhl; P Berberat; M Abou-Shady; M Martignoni; S E Anghelacopoulos; A Zimmermann; M W Büchler
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

2.  Quantitative proteomics investigation of pancreatic intraepithelial neoplasia.

Authors:  Sheng Pan; Ru Chen; Beth Ann Reimel; David A Crispin; Hamid Mirzaei; Kelly Cooke; Joshua F Coleman; Zhaoli Lane; Mary P Bronner; David R Goodlett; Martin W McIntosh; William Traverso; Ruedi Aebersold; Teresa A Brentnall
Journal:  Electrophoresis       Date:  2009-04       Impact factor: 3.535

3.  Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers.

Authors:  Reza Ehsanian; Carter Van Waes; Stephan M Feller
Journal:  Cell Commun Signal       Date:  2011-05-15       Impact factor: 5.712

4.  Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine.

Authors:  P L de Souza; M Castillo; C E Myers
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Control of the growth of human breast cancer cells in culture by manipulation of arachidonate metabolism.

Authors:  Rasha Hammamieh; Dena Sumaida; XiaoYan Zhang; Rina Das; Marti Jett
Journal:  BMC Cancer       Date:  2007-07-25       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.